Diana Ernst, RPh

Most Recent Articles by Diana Ernst, RPh

FDA Approves Rituxan Hycela to Treat Three Blood Cancers

By Jun 22, 2017

The subcutaneous injection is for the treatment of follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.

New Antibiotic Baxdela Gets FDA Approval

By Jun 19, 2017

Baxdela, a fluoroquinolone antibiotic, is active against both Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus.

Symjepi Approved for Emergency Anaphylaxis Treatment

By Jun 16, 2017

Symjepi should only be injected into the anterolateral aspect of the thigh; injection into other areas such as the buttocks or the hands and feet may result in adverse effects and may also not provide effective treatment of anaphylaxis.

Recall Issued for Allergy Nasal Spray

By Jun 14, 2017

While testing did not reveal the presence of the microorganism, the recall is being conducted out of an abundance of caution, as use of contaminated product can be especially concerning for immunocompromised patients.

Soliqua Beats Basal Insulin for HbA1c Reduction Regardless of Level at Screening

By Jun 13, 2017

After 30 weeks, least squares (LS) mean reductions in HbA1c for the Soliqua 100/33 treatment groups were 1.09%, 1.44% and 2.41%, respectively.

More Articles by Diana Ernst, RPh